Welcome

Coherus, Amgen Settle Patent Suit on Arthritis Biosimilar Drug

Nov. 26, 2019, 6:55 PM

Coherus and Amgen dropped a lawsuit in which Coherus claimed Amgen’s biosimilar of AbbVie’s blockbuster arthritis drug Humira infringes four patents for its own biosimilar version.

  • No further details were provided in a notice of agreement, approved Tuesday in federal court in Wilmington, Delaware
  • Amgen launched Amgevita, a biosimilar of Humira, in Europe in October 2018
    • Amgevita is sold only in Europe but is made in the U.S., which Coherus alleged as infringement of its patents
  • Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
  • Amgen’s U.S. version, called Amgevita, won’t come to market ...





To read the full article log in.

Learn more about a Bloomberg Law subscription.